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1<ABSTRACT>
Development of novel infectious clones of genotype 1 hepatitis C virus
Bora Jin
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Sang Hoon Ahn)
Background & Aims: Hepatitis C virus (HCV) research has been hampered by 
the inability to culture HCV isolates in vitro except for the genotype 2a JFH1. 
Thus, it is important to develop cell culture-infectious clones for various HCV 
genotypes and to study cell culture-adaptive mutations which would enable 
development of infectious HCV clones. Among cell culture-adaptive mutations,
S2204I robustly enhances HCV RNA replication in most HCV genotypes but
the relevant mechanism is still unclear. Recent studies identified four cell 
culture-adaptive mutations F1464L/A1672S/D2979G/ Y2981F (LSGF) that 
permit many HCV isolates to be further adapted in cell culture. In this study,
LSGF mutations were used as the first step for developing genotype 1 infectious 
clones and we also investigated the effect of S2204I mutation on viral RNA 
replication.
Method: Multiple cell culture-adaptive mutations including LSGF were 
introduced into genotype 1a and 1b HCV sequences. We also generated various 
recombinant chimeras with or without S2204I mutation. And we generated 
genotype 1a constructs including substitutions at position 2204 (threonine and 
2serine) which were found in the chimpanzee-infection experiment. Huh7.5 cells 
were transfected with in vitro-transcribed viral RNA and HCV RNA replication 
was evaluated by Gaussia luciferase reporter assay.
Results: LSGF mutations did not confer the RNA replication ability of H77C 
and H77S.3 (genotype 1a). Con1 (genotype 1b) that was introduced with 
multiple cell culture-adaptive mutations including LSGF showed a low RNA 
replication level. The RNA replication of H77S-based JFH1 chimeras in 
transfected cells was impaired regardless of S2204I mutation. RNA replication
level of H77S.3 with either threonine or serine at position 2204 was similar to 
each other.
Conclusion: LSGF mutations did not increase RNA replication capacities of 
H77C, H77S.3 and Con1. Capability of S2204I mutation in enhancing HCV 
RNA replication was not dependent on background genotypes. Serine and 
threonine at position 2204 supported HCV RNA replication similarly in in-vitro
transfection experiments.
----------------------------------------------------------------------------------------------------------
Key words: hepatitis C virus, cell culture-adaptive mutation, cell culture-infectious 
clone, RNA replication
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I. INTRODUCTION
Approximately 130–170 million people globally are living with 
hepatitis C virus (HCV). HCV is a major cause of acute and chronic liver 
disease including cirrhosis, hepatocellular carcinoma and liver failure. The 
annual death of HCV-related liver diseases is more than 350,000. HCV is 
classified as genus Hepacivirus within Flaviviridae family which has 
characteristics of enveloped, positive-strand RNA virus. The HCV RNA 
genome is 9.6 kb in length and encodes a single long ORF. The ORF encodes 
three structural proteins (Core, E1, and E2), and seven nonstructural (p7, NS2, 
NS3, NS4A, NS4B, NS5A, NS5B) proteins.1
HCV isolates have been classified into seven major variants (genotype 
1-7) and numerous subtypes (a, b, etc.). HCV genotypes have the sequence 
heterogeneity of 31% to 33% and the subtypes have that of 20% to 25%.2
Genotype 1 is the most common type of HCV in North America, Northern and 
Western Europe, South America, Asia and Australia. In South Korea, about 50% 
HCV infection is caused by genotype 1b virus.3
The current standard therapy for HCV infection which consists of
4pegylated interferon alpha in combination with ribavirin is poorly tolerated and 
effective in only 50% of genotype 1 virus-infected patients.4 Since 2011, triple 
combination therapy that included NS3 protease inhibitors has been approved 
for HCV genotype 1 infections.5,6 However, the NS3 protease inhibitor has 
shown severe side effects, resistance and drug-drug interactions and have 
different efficacy in varied HCV genotypes.7
One major problem in HCV research is the inability to culture patient 
isolates in vitro.8 Only JFH1 (genotype 2a) is able to spontaneously replicate
and release infectious virus particles in human hepatoma cell lines (Huh7 and 
its derivatives).9,10 Because of these reasons, it requires alternative approaches
for HCV research.
One of the alternative approaches is the replicon system which 
supports HCV RNA replication without production of infectious virus particles. 
The first subgenomic replicon system was made using Con1 (genotype 1b) and 
allows persistent RNA replication in Huh7.11 Several cell culture-adaptive 
mutations were identified through a selection process of this replicon 
system.10,12 Among these mutations, S2204I mutation efficiently enhances RNA 
replication level. And this enhancing capacity has been proved in many 
different HCV genotypes including genotype 1a;13 genotype 1b;12 genotype 
3a;14,15 genotype 4a;15,16 genotype 5a;17 genotype 6a.18 However, the mechanism 
of how S2204I enhances HCV RNA replication in human hepatoma cell lines 
still remains unclear and needs further investigation.
While the replicon system supports only HCV RNA replication, the 
cell culture-infectious clone can produce infectious virus particles, which is 
available in only a few genotypes such as JFH110 and H77S.19 H77S, whose 
prototype is H77C, has five cell culture-adaptive mutations.19 These mutations 
include two within NS3 (Q1067R, V1651I), one in NS4A (K1691R), and two in 
NS5A (K2040R, S2204I).19 Unfortunately, the H77S is not so efficient to be 
used in researches because of poor production of infectious virus particles.20
5A recent study has reported development of efficient cell culture-
infectious clones of genotype 2a and 2b.21 These clones have several cell 
culture-adaptive mutations, and four mutations of them primarily contribute to 
viral viability.21 The four mutations are designated LSGF (F1464L in NS3, 
A1672S in NS4A, D2979G in NS5B and Y2981F in NS5B).21 The same 
researchers developed another efficient cell culture-infectious clone for
genotype 1a (TNcc) using LSGF.22 LSGF mutations enabled development of
efficient cell culture-infectious clones of HCV genotype 2a (J6cc)21 and 2b 
(J8cc, DH8cc, and DH10cc)21,23 as well as 5-5A recombinants with JFH1 
NS5B-3’UTR for genotypes 3a(S52), 4a(ED43), 5a(SA13), and 6a(HK6a).24
Thus, introducing LSGF could be the first step of the cell culture-adaptation
process for other HCV isolates. 
In this study, I attempted to use the LSGF mutations to generate 
genotype 1 cell culture-infectious clone. Furthermore, we investigated the effect 
of cell culture-adaptive mutations of NS5A on the HCV RNA replication. 
6II. MATERIALS AND METHODS
1. Plasmids 
pH77C is the first HCV genomes found to be infectious, as 
demonstrated by intrahepatic transfections in chimpanzees.25 pH77S, a cell
culture-infectious clone for genotype 1a HCV was described previously.13
pH77S.3 is a modified version of this plasmid that has an enhanced capacity for 
the production of infectious virus in cell culture and that contains an additional 
N476D mutation in E2 and lacks the Q1067R adaptive mutation in NS3.26
pCon1 was cloned from viral RNA isolated from an HCV infected human liver 
and has been used to construct subgenomic selectable replicons.11 pH77S/AAG
contains a lethal mutation in its RNA polymerase.13 pH77D contains the I2204S 
substitution, eight TNcc-derived mutations22 and three additional compensatory 
mutations in the H77S.3 background.27 H77S/J5A is that the entire NS5A 
sequence was exchanged between H77S and JFH-1.28 The H77D/J5A was 
generated by inserting a Bsu36I/HindIII restriction NS5A fragment of 
H77S/J5A.28 To insert the Gaussia luciferase (GLuc)-coding sequence between 
p7 and NS2 in pCon1, followed by the foot-and-mouth disease virus 2A
(FMDV2A) protein-coding sequence which is an autocleaving peptide, XbaI
restriction sites were created between the p7 and NS2 coding sequences by 
site-directed mutagenesis. DNA coding for GLuc was subcloned into the XbaI
sites of the modified plasmid after PCR amplification using the primers: 5’-
ATG CTC TAG AAT GGG AGT CAA AGT TCT GTT TGC-3’(sequence 
corresponding to the N-terminal GLuc is italicized and that corresponding to 
XbaI underlined) and 5’-ATG CTC TAG AGG GCC CTG GGT TGG ACT C 
-3’(C-terminal GLuc italicized and XbaI underlined). The annealed
oligonucleotides were digested by restriction enzyme and the product inserted 
into the corresponding sites of pCon1 to generate pCon1/GLuc2A. The 
7H77C/GLuc2A was generated by inserting an AfeI/AscI restriction fragment 
containing the GLuc2A sequence between the corresponding sites of 
pH77S.3/GLuc2A.
2. Cells 
Huh7.5, a subline of Huh7, was grown in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM, Welgene, Daegu, Korea) containing 10% 
fetal bovine serum (FBS, Gibco, Grand Island, NY, USA), penicillin and 
streptomycin (Welgene) at 37°C in a 5% CO2 environment.
3. Mutagenesis PCR
The cell culture adaptive mutations were generated by Quick Change 
Site-Directed Mutagenesis Kit (Agilent Technology, Santa Clara, CA, USA) and 
Quick Change Lightning Multi Site-Directed Mutagenesis Kit (Agilent 
Technology, Santa Clara, CA, USA) using the following mutagenesis primers
(Table 1,2).
4. RNA transcription and transfection 
pH77C, pH77S.3, pH77D were linearized by XbaI restriction digestion.
pCon1 was linearized by ScaI restriction digestion. Then, synthetic RNA was 
transcribed with T7 MEGA-Script kit (Promega, Madison, WI, USA) after 
linearizing plasmid with XbaI (New England Biolabs, Ipswich, MA, USA) or 
ScaI (New England Biolabs). Following treatment with RNase-free DNase to 
remove template DNA and precipitation of the RNA within lithium chloride, the 
RNA was transfected into Huh7.5 cells Twenty-four hours before transfection, 3 
x 105 cells per well were seeded in 6-well culture dishes. Briefly, 1.25 mg of in 
vitro-transcribed RNAs were mixed with TransIT-mRNA transfection reagent
and boost reagent (Mirus Bio LLC, Madison, WI, USA) in 250 µL Opti-MEM 
8(Gibco, Rockville, MD, USA). The mixture were incubated for 3 min at room
temperature, and added dropwise into the Huh7.5 cells. Six hours after 
transfection, the culture medium was replaced with fresh medium and the 
supernatant was collected at different time points (24, 48, 72 h).
5. Gaussia luciferase reporter assay
Secreted GLuc activity in the supernatant was measured by a BioLux 
Gaussia Luciferase Assay Kit (New England Biolabs).  GLuc assay solution 
was prepared by adding BioLuxGLuc Substrate to BioLuxGLuc Assay Buffer 
(1:100) and mix well by inverting. Luminescence was measured after shaking 
(1 sec), delay (5 sec) and integration (10 sec). Twenty microliters of collected 
supernatant were transferred into 96-well white plates. Fifty microliters of GLuc 
assay solution were added to the supernatant and the luminescence signal was 
promptly measured by using micro-plate reader.  
9Table 1. Sequence of multi-site directed mutagenesis PCR primers for cell 
culture adaptive mutations
Background Mutations
Forward Primer Sequence
(5’→3’)
H77C
H77S.3
F1464L
TGT GTC ACT CAG ACA GTC GAT TTA AGC 
CTT GAC CCT
A1672S GGC TGC TCT GGC CTC GTA TTG CCT GTC
D2979G
Y2981F
CTA CAG CGG GGG AGG CAT TTT TCA CAG 
CGT GTC TC
Con1
A1226G
GAC ATT CCA GGT GGG CCA TCT ACA CGC 
CC
F1464L
CAC CCA GAC AGT CGA CTT AAG CCT GGA 
CC
A1672S
CTA GCA GCT CTG GCC TCG TAT TGC CTG 
ACA A
Q1773H
TTT CAT CAG CGG GAT ACA TTA TTT AGC 
AGG CTT GTC C
G1909S CAC GTG GGC CCA AGC GAG GGG GCT GTG
N1927T GCT TCG CGG GGT ACC CAC GTC TCC C
S2204I
TTG GCC AGC TCA TCA GCT ATC CAG CTG 
TCT G
D2415G GAG GCT AGT GAG GGC GTC GTC TGC TGC
S2962D CTC CAA 
D2978G
GTT ACA GCG GGG GAG GCA TAT ATC ACA 
GCC TG
Y2980F
AGC GGG GGA GGC ATA TTT CAC AGC CTG 
TC
W2994S CCG CTG GTT CAT GTC GTG CCT ACT CCT AC
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Table 2. Sequence of site directed mutagenesis PCR primers for cell culture 
adaptive mutations
Background Mutations
Primer Sequence
(5’→3’)
H77S.3
I2204S
Forward
CAG CTC CTC GGC TAG CCA GCT GTC
CGC TCC ATC TCT C
Reverse
GAG AGA TGG AGC GGA CAG CTG GCT
AGC CGA GGA GCT G
I2204T
Forward
CTA TGG CCA GCT CCT CGG CTA CCC
AGC TGT CCG CTC CAT C
Reverse
GAT GGA GCG GAC AGC TGG GTA GCC
GAG GAG CTG GCC ATA G
H77D/J5A S2204I
Forward
GCG AGC TCC TCA GTG ATC CAG CTA 
TCA GCA CC
Reverse
GGT GCT GAT AGC TGG ATC ACT GAG 
GAG CTC GC
11
III. RESULTS
1. Effect of cell culture-adaptive mutations on RNA replication of 
genotype 1a HCV
In this study, I initially attempted to use the LSGF mutations to 
generate a genotype 1a cell culture-infectious clone. Genotype 1a strain H77C 
which is the first HCV genome found to be infectious in chimpanzees with the 
RNA transcripts was selected.25 The LSGF mutations were introduced into 
H77C, which did not enhance RNA replication in Huh7.5 cells. To compare
RNA replication levels between the mutant construct (H77C/LSGF) and the 
wild-type (H77C) virus, synthetic RNA transcribed from these plasmid DNAs
were transfected into Huh7.5 cells. The RNA replication efficiency of each 
construct was evaluated by GLuc reporter assay. GLuc assay is a 
well-established reporter assay for evaluating RNA replication efficacy.26,31
H77S.3, which supports RNA replication, was used as a positive control.26
H77S/AAG, which contains a lethal mutation in its RNA polymerase, was used 
as a negative control.13 As expected, wild-type H77C RNA did not replicate at 
all in Huh7.5. H77C that was introduced with LSGF mutations had similar RNA 
replication level compared to that of wild-type H77C (Fig. 1A).
Then, I used H77S.3 which has five cell culture-adaptive mutations in 
H77C. Although H77S.3 has an ability to produce infectious particles, its 
infectious titer is relatively low compared to that of TNcc.19,26,27 Therefore, I
introduced LSGF mutations into H77S.3 to determine whether they would 
increase the RNA replication level. However, H77S.3/LSGF failed to replicate, 
and removal of S2204I, which is a key adaptive mutation of H77S.319, also 
failed to replicate (Fig. 1B).
Taken together, LSGF mutations did not increase the RNA replication 
ability of H77C and negatively affected RNA replication of H77S.3 in Huh7.5. 
12
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Figure 1. Effect of cell culture-adaptive mutations (LSGF) on the RNA 
replication level of genotype 1a HCV. (A) Top, red arrowheads indicate H77C
genome containing the LSGF mutations. (B) Top, purple arrows show cell 
culture-adaptive mutations in H77S.3. LSGF mutations and removal of S2204I 
substitution are indicated by red arrowheads and red arrow respectively. (A and 
B) Graphs show Gaussia luciferase activity in Huh7.5 cell lines at 6, 24, 28, 72 
hours post transfection with the indicated RNAs encoding GLuc. Data 
represent means ± s.d. from duplicate experiments. RLU; relative light units.
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2. Effect of cell culture-adaptive mutations on RNA replication of 
genotype 1b HCV
Recently, Yamane et al. developed an efficient cell culture-infectious
clone for genotype 1a, H77D, using cell culture-adaptive mutations. H77D 
contains the I2204S substitution, eight TNcc-derived mutations and three 
additional compensatory mutations (G1909S in NS4B, D2416G in NS5A and 
G2963D in NS5B) in the H77S.3 background.27 H77D efficiently produced 
infectious virus particles and its RNA replication level was 10 times higher than 
that of TNcc.22,27 So, I focused on developing other infectious clone with 
different genotypes. 
In South Korea, about 50% of HCV infection is caused by genotype 1b 
virus. The first replicon system was made using Con1 (genotype 1b) isolate and 
allowed persistent RNA replication in Huh7.11 Several cell culture-adaptive 
mutations were identified in the replicon system. Among these, S2204I 
mutation efficiently promoted viral RNA replication. but could not produce 
infectious particles.12 Thus, I attempted to develop a novel cell 
culture-infectious clone for genotype 1b Con1.
LSG has more potent ability to increase the RNA replication level than 
F21. For this reason, I prioritized to generate Con1 with LSG (Con1/LSG). Con1
containing S2204I mutation was used as a positive control (Con1/SI). The RNA
replication level of Con1/LSG slightly increased compared to that of wild type, 
however, it was still lower than that of Con1/SI (Fig. 2A).
Next, I added three mutations, including G1909S in NS4B, D2415G in 
NS5A and S2962D in NS5B, which are derived from H77D, and added F from
the LSGF into Con1/LSG. While the amino acid at 2963 (2962 in Con1) is 
glycine and this was substituted by serine in H77D, the amino acid at 2962 in 
Con1 is serine. Since serine is a phosphorylatable amino acid, I tried both serine 
(no substitution) and aspartic acid (S2962D) at 2962. Thus, I generated two 
15
kinds of Con1 constructs (Con1/LSG/SGFD and Con1/LSG/SFG). However, 
neither of them replicated efficiently as Con1/SI (Fig. 2B). 
Finally, I added four more mutations which are derived from TNcc 
excluding LSGF into the two prior Con1 constructs. The four mutations were
designated TNm (A1226G in NS3, Q1773H in NS4B, N2927T in NS5B and 
W2994S in NS5B). Thus, Con1/10mt is a mutant construct that was introduced 
with LSGF, SG derived from H77D and TNm into Con1. Con1/11mt contains 
another mutation (S2962D) in Con1/10mt (Fig. 2C). Compared to Con1/SI, 
Con1/10mt and Con1/11mt poorly replicated (Fig. 2C). Presence of S2962D 
made negligible differences in RNA replication level (Fig. 2B and 2C). 
Therefore, eight mutations derived from TNcc22 and three mutations derived 
from H77D27 did not enhance RNA replication of Con1.
16
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Figure 2. Effect of cell culture-adaptive mutations on the RNA replication level
of genotype 1b HCV.(A, B and C) Top, Schematic diagrams of Con1 genomes
with cell culture adaptive mutations. S2204I substitution, the TNcc-derived 
mutations and the H77D-derived mutations are indicated by black arrowhead, 
red arrowheads and green arrowheads respectively. (A, B and C) Bottom, 
Gaussia luciferase activity determined in Huh7.5 cell lines at 6, 24, 28, 72 
hours post transfection with the indicated RNAs encoding GLuc. Data 
represent means ± s.d. from duplicate experiments. RLU; relative light units.
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3. Effect of cell culture-adaptive mutation S2204I on HCV RNA
replication 
Replacement of viral proteins between other genotypes/subtypes is a 
common method to study the function of viral proteins. This approach was used
to study NS5A protein by some laboratories.28,35,36 Interestingly, in these 
investigations, two research groups have reported conflicting results. Both 
studies used the same HCV chimeras designated JFH1/H5A, which contains 
NS5A from H77 (genotype 1a) in the background of JFH1 (genotype 2a). When 
the RNA transcribed from this chimeric DNA was transfected into 
Huh7-derived cell line, Okamoto et al.35 showed that the RNA replication of 
this construct was comparable to that of JFH1, whereas Kim et al.28 showed a 
significant impairment in RNA replication capacity.
We previously investigated why these two results were different and 
found that the presence or absence of S2204I cell culture-adaptive mutation was 
the major reason. Our result indicated that S2204I mutation impaired HCV 
RNA replication when it is placed in the JFH1 background. Although S2204I 
mutation has positive effects on the RNA replication of most HCV replicon 
systems, it negatively affected JFH1 RNA replication.37
We hypothesized that S2204I mutation has different effects on HCV 
RNA replication depending on background genotypes. To test this hypothesis, 
we generated two chimeras which contain NS5A from JFH1 (genotype 2a) in 
the background of H77S (genotype 1a). One chimera had the S2204I mutation 
(H77S/J5A/SI), while the other chimera did not (H77S/J5A) (Fig. 3A). RNA
replication level of H77S/J5A/SI was expected to be higher than that of 
H77S/J5A because S2204I mutation enhances RNA replication of H77S. The 
result showed that RNA replication of H77S/J5A was decreased (Fig. 3B) and
S2204I also failed to increase the RNA replication level of H77S/J5A (Fig. 3B).
We tried the same approach of swapping NS5A in the background of
H77D27 (Fig. 3C). S2204I mutation is known to decrease the RNA replication 
20
levels of H77D.27 Two generated chimeras (H77D/J5A and H77D/J5A/SI) failed 
to replicate in Huh7.5 cell. (Fig. 3D)
4. In vitro HCV RNA replication fitness of IS & IT reversion mutants
In a recent study, evolution of genotype 1a virus containing 6 cell 
culture-adaptive mutations (H77S.2) was observed in an infected chimpanzee.38
Isoleucine at position 2204 (S2204I mutation) was replaced to threonine 8 
weeks after infection with H77S.238 and 62 weeks later, the original S2204I cell 
culture-adaptive mutation completely reverted to the wild-type serine.38
Two constructs were generated to assess how the substitution of 
threonine at position 2204 influences RNA replication in cell culture compared
to serine. One had the serine at position 2204 in H77S.3 (designated H77S.3/IS) 
and the other had threonine (designated H77S.3/IT) (Fig. 3A). RNA replication 
levels of both constructs were decreased by more than 10 fold at 48 hours and at
72 hours post-transfection compared to that of H77S.3 (Fig. 3B). But, the RNA 
replication level of both IS and IT constructs was similar to each other (Fig. 
3B).
21
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Figure 3. Effect of mutations in NS5A on the RNA replication level. (A and C) 
Schematic presentation of recombinant constructs. (B and D) Gaussia 
luciferase activity determined in Huh7.5 cell lines at 6, 24, 28, 72 hours post 
transfection with the indicated RNAs encoding GLuc. Data represent means ± 
s.d. from duplicate experiments. RLU; relative light units.
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IV. DISCUSSION
The aims of this study are to develop novel genotype 1 cell culture-
infectious clones and to investigate the effect of cell culture-adaptive mutations
of NS5A on the HCV RNA replication.
Since discovery of the genotype 2a JFH1 strain10, numerous trials have
been done to develop infectious clones for other HCV genotypes. As 
approxamately 60% of HCV infections are caused by genotype 1 viruses in the
world3, it is essential to develop genotype 1 cell culture-infectious clone for
HCV research. Recently, Yi et al. identified four mutations, designated LSGF
(F1464L/A1672S/D2979G/ Y2981F) and they are the key factors to enhance 
viability of HCV genotypes 1a (TNcc),22 2a (J6cc),21 and 2b (J8cc, DH8cc, and 
DH10cc).21,23 I attempted to develop efficient genotype 1a cell 
culture-infectious clone by introducing LSGF mutations and the method that 
was used to develop J6cc,21 TNcc.22
Genotype 1a strain H77C was selected because of the following two 
reasons. One is that the RNA transcript of H77C was the first HCV genome 
found to be infectious in chimpanzees.25,39 And the other is its various
applications in HCV research, for example, studying viral entry using HCV-like 
particles,40 development of HCV pseudo-particles.41
LSGF mutations were introduced into H77C (H77C/LSGF).
Unfortunately, RNA replication of H77C/LSGF was not observed in transfected 
cultures (Fig. 1A). While I am working on this, Yi et al. developed a cell 
culture-infectious clone for H77C (H77Ccc)43 using a recombinant chimera 
between H77C (5’UTR-NS5A) and JFH1 (NS5B-3’UTR), and introducing
mutations derived from TNcc.22 H77Ccc, which contains a total of 19 cell 
culture-adaptive mutations, is able to replicate and spread in cell culture.43
Introducing LSGF mutations into the recombinant seems to be a better way than 
that into H77C full-length.
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H77S.3/LSGF was generated to investigate whether introducing LSGF 
mutations enhance the RNA replication level of H77S.3 which already has five 
cell culture-adaptive mutations in H77C background.26 Production of infectious 
particle by H77S.3 was poor (~3 log focus-forming units/ml)26 compared to that 
of JFH1-QL (~6 log focus-forming units/ml)27 and TNcc (~5 log focus-forming 
units/ml).22 H77S.3/LSGF failed to replicate in Huh7.5 cells (Fig. 1B). LSGF 
mutations conferred a negative effect on RNA replication of H77S.3 (Fig. 1B).
H77S.3/LSGF/IS, in which S2204I mutation was reverted to the wild-type 
serine, also failed to replicate (Fig. 1B). Taken together, LSGF did not enhance 
H77C RNA replication regardless of five cell culture-adaptive mutations of 
H77S.3. 
While I am working on development of novel genotype 1 cell 
culture-infectious clone, a further adapted genotype 1a virus (H77D) that
efficiently replicates and produces infectious particles in cell culture was 
reported.27 H77D was generated by introducing eight TNcc mutations (LSGF 
and TNm)22 and additional three mutations into the H77S.3 background27. RNA
replication of H77S.3/LSGF/TNm was inhibited, but removal of the S2204I
adaptive mutation from the original H77S.3 initiated RNA replication and this 
genome was passaged until high titer viruses emerged.27 Continued passage of 
cells transfected with this RNA found additional mutations in NS4B (G1909S), 
NS5A (D2416G) and NS5B (G2963D) that together enhanced RNA replication
by 10 fold than that of TNcc. Compared to our study, introducing TNm 
mutations into H77S.3/IS/LSGF restored low-level RNA replication.27 Thus, I
assumed that TNm mutations played a positive role to restore the RNA
replication level.
Since highly efficient cell culture-infectious clones of genotype 1a 
(H77D, H77Ccc) were developed, I focused on the development of other cell 
culture-infectious clone with different genotypes. Especially, genotype 1b 
causes 50% of HCV infection in South Korea.3 The nucleotide sequences of 
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genotype 1b are 90% to 93% identical to those of genotype 1a. Con1 is the first 
strain of replicon system.11 Thus, I attempted to approach in the same way to
develop genotype 1b cell culture-infectious clone using Con1 strain. 
I introduced eight mutations derived from TNcc22 and three mutations
derived from H77D22 into Con1 (Fig. 2A, 2B and 2C). Unfortunately, RNA
replication capacity of the construct was not increased. Perhaps, a different 
method should be tried in order to develop cell culture-infectious clone for
genotype 1b.
S2204I mutation efficiently promotes viral RNA replication in 
genotype 1a,13 1b,12 3a,14,15 4a,15,16 5a,17 6a18 viruses. However, S2204I has a 
negative effect on the RNA replication of genotype 2a JFH1. The result 
indicates that S2204I mutation impairs RNA replication when it is placed in the 
JFH1 background. 
Combined with our previous observation, we hypothesized that S2204I 
mutation has different effects on HCV RNA replication depending on the 
background genotypes. Thus, we anticipated that RNA replication level of 
H77S/J5A/SI is higher than that of H77S/J5A because S2204I positively affects 
H77S which is the background of these chimeras. However, RNA replication of 
these two constructs was defective regardless of S2204I mutation (Fig. 3B). 
S2204I also negatively affects RNA replication of H77D.27 H77D/J5A failed to 
replicate and introducing S2204I mutation into H77D/J5A did not restore the 
RNA replication (Fig. 3D). Therefore, the effect of S2204I mutation on HCV 
RNA replication does not entirely depend on the background genotypes.
Alhough S2204I enhances HCV RNA replication in most HCV 
genotypes in vitro isolecine was reverted to the wild-type serine 62 weeks after 
infection of chimpanzees.38 This reversion occurred in two steps. Firstly
isoleucine was substituted with threonine, and then threonine mutated to 
serine.38 We considered that serine is more fit than threonine. To test this, we 
compared the RNA replication level of H77S.3 containing serine at 2204 
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(H77S.3/IS) and H77S.3 containing threonine at the same position (H77S.3/IT)
(Fig. 3B). Both substitutions (H77S.3/IS and H77S.3/IT) reduced RNA
replication (Fig. 3B), and serine and threonine seem to have similar roles in 
in-vitro viral RNA replication.
27
V. CONCLUSION
Introducing LSGF mutations, which confer positive effects on RNA 
replication of several HCV genotypes, did not increase RNA replication levels
of H77C and H77S.3. Likewise, multiple cell culture-adaptive mutations did 
not increase RNA replication level of Con1. S2204I mutation seems to play a 
role which is independent on background genotypes. Serine and threonine at 
2204 may have similar roles in HCV RNA replication in vitro.
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<ABSTRACT(IN KOREAN)>
감염성 있는 유전자형 1 C형 간염 바이러스의
새로운 클론 제작
<지도교수 안 상 훈>
연세대학교 대학원 의과학과
진 보 라
배경 및 목적: 환자에서 분리한 C형 간염 바이러스(HCV)는 유전자형
2인 JFH1을 제외하고, 세포 배양 내에서 HCV RNA 복제가 불가능하
기 때문에 연구에 어려움이 있다. 그러므로 세포 배양 내에서 배양할
수 있는 다양한 유전자형 HCV 클론의 제작과 이에 필수적인 cell 
culture-adaptive 변이를 찾는 연구가 매우 중요하다. Adaptive 변이
중 많은 유전자형 바이러스의 RNA 복제 능력을 향상시키는 S2204I 
변이는 아직 그 메커니즘이 정확히 밝혀지지 않았다. 최근 연구에서
는 네 가지 adaptive 변이 F1464L/A1672S/D2979G/Y2981F (LSGF)
를 찾아냈고, 이는 여러 감염성 있는 클론의 제작에 효율적으로 작용
했다. 본 연구에서는 LSGF 변이를 이용하여 다양한 감염성 있는 유
전자형 1 클론을 제작하고자 하였고, S2204I 변이가 세포 배양 내에
서 어떻게 복제 능력을 향상시키는지 알아보고자 하였다. 
방법: 여러 cell culture-adaptive 변이를 적용시킨 유전자형 1a, 1b
플라스미드를 제작했고 S2204I 변이를 적용시켰다. 그리고 HCV 
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RNA를 감염시킨 침팬지에서 찾아낸 변이(2204번째 트레오닌, 세린)
를 유전자형 1a HCV 플라스미드에 적용시켰다. 제작한 재조합 플라
스미드 DNA로부터 만들어진 in-vitro transcribed RNA를 Huh7.5 세
포에 transfection 시킨 후 Gaussia lucifease reporter assay를 통해
RNA 복제 능력을 측정하였다.
결과: LSGF 변이는 유전자형 1a인 H77C와 H77S.3의 RNA 복제 능
력을 향상시키지 못하였다. 유전자형 1b인 Con1에는 LSGF를 포함한
여러 변이를 적용시켰고, 미미한 RNA 복제 레벨을 보였다. H77S의
NS5A를 JFH1의 NS5A로 바꾼 키메라는 S2204I 변이와 관계없이
RNA 복제가 일어나지 않았다. 트레오닌 또는 세린을 가진 H77S.3의
RNA 복제는 비슷한 정도를 보였다.
결론: LSGF변이는 H77C, H77S.3 그리고 Con1의 RNA 복제 능력을
향상시키지 못한다. S2204I의 RNA 복제에 대한 영향은 배경 유전자
형과는 독립적으로 작용한다. 2204번째 세린과 트레오닌은 세포 배양
내 HCV RNA 복제에 있어서 비슷한 역할을 할 것이라고 생각된다.
---------------------------------------------------
핵심되는 말: C형 간염 바이러스, cell culture-adaptive 변이, 감염성
있는 클론, 바이러스 복제
